Skycovion COVID-19 vaccine authorized by MHRA

SKYcovion, the COVID-19 vaccine developed by SK bioscience, an entity of South Korean firm SK Chemicals, has been cleared for marketing by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

It becomes the eighth COVID-19 vaccine authorized by the UK’s independent medicines regulator. The authorization follows advice received from the independent Commission on Human Medicines (CHM).

The SKYcovion vaccine combines a part of the SARS-CoV-2 virus spike protein with an ‘adjuvant’ – an additional ingredient designed to trigger a stronger immune response. It is given as two injections, four weeks part.